How Stengone was paid
$3.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Carmine N. StengonePresident and Chief Executive Officer | $655,620 | — | $2,291,640 | $450,739 | $11,449 | $3,409,448 |
| Peter T. SloverChief Financial Officer | $487,487 | — | $840,268 | $238,869 | $11,279 | $1,577,903 |
| Timothy R. Watkins, M.D., MSc.Chief Medical Officer and Head of Development | $359,501 | $225,000 | $984,556 | $176,085 | $18,181 | $1,763,323 |
What changed and why
- $3.4MCarmine N. Stengone total compensation decreased to $3,409,448 in fiscal year 2025 from $4,900,039 in 2024.
- 125%Corporate goals for the 2025 short-term incentive program were achieved at 125% of target level.
- Stock option awards served as the sole long-term equity incentive component for named executive officers in 2025.
- Timothy R. Watkins joined the company as Chief Medical Officer and Head of Development in April 2025.
- 4%A non-elective safe harbor 401(k) contribution of 4% on eligible compensation was provided to employees.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.